JP2016527225A - ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 - Google Patents

ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 Download PDF

Info

Publication number
JP2016527225A
JP2016527225A JP2016526580A JP2016526580A JP2016527225A JP 2016527225 A JP2016527225 A JP 2016527225A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016527225 A JP2016527225 A JP 2016527225A
Authority
JP
Japan
Prior art keywords
upa
antibody
kabat
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016526580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527225A5 (enExample
Inventor
セーアン・パドキャー
イェスパー・パス
グスタフ・ローダー
カスパー・アルムホルト
ペニーレ・アウツェーン・ウシャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2016527225A publication Critical patent/JP2016527225A/ja
Publication of JP2016527225A5 publication Critical patent/JP2016527225A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016526580A 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 Withdrawn JP2016527225A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13176519.0 2013-07-15
EP13176519 2013-07-15
US201361847664P 2013-07-18 2013-07-18
US61/847,664 2013-07-18
PCT/EP2014/065136 WO2015007727A1 (en) 2013-07-15 2014-07-15 Antibodies that bind urokinase plasminogen activator

Publications (2)

Publication Number Publication Date
JP2016527225A true JP2016527225A (ja) 2016-09-08
JP2016527225A5 JP2016527225A5 (enExample) 2017-08-10

Family

ID=48783103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526580A Withdrawn JP2016527225A (ja) 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体

Country Status (6)

Country Link
US (1) US9908944B2 (enExample)
EP (1) EP3022229A1 (enExample)
JP (1) JP2016527225A (enExample)
CN (1) CN105612183A (enExample)
TW (1) TW201536810A (enExample)
WO (1) WO2015007727A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
EP3459974B1 (en) * 2017-09-21 2025-02-19 Guy L. Reed Specific plasmin inactivation by anticatalytic antibody
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN111253486B (zh) * 2018-09-27 2023-09-29 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
CN110343665B (zh) * 2019-05-05 2023-07-14 吉林大学 一种car-t细胞及其应用
US20230220112A1 (en) * 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN114917329B (zh) * 2021-02-11 2023-07-21 兰州大学第二医院 抗cd87抗体与抗pd1抗体联合治疗胃癌
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP2025168320A (ja) * 2024-04-26 2025-11-07 イーライ リリー アンド カンパニー タンパク質チロシンキナーゼ７抗体及び抗体－薬物コンジュゲート

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009035532A (ja) * 2001-12-28 2009-02-19 Chugai Pharmaceut Co Ltd タンパク質安定化方法
JP2012082201A (ja) * 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体
US20120328511A1 (en) * 2011-04-07 2012-12-27 Amgen Inc. Novel Antigen Binding Proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
EP1406652A2 (en) 2001-07-10 2004-04-14 Omnio AB Novel drug targets for arthritis
WO2005048822A2 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
EP1814914A2 (en) 2004-10-29 2007-08-08 The Regents of the University of Colorado Antibodies that bind urokinase-type plasminogen activator and epitopes therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009035532A (ja) * 2001-12-28 2009-02-19 Chugai Pharmaceut Co Ltd タンパク質安定化方法
JP2012082201A (ja) * 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体
US20120328511A1 (en) * 2011-04-07 2012-12-27 Amgen Inc. Novel Antigen Binding Proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOUSE G. ET AL., J. BIOL. CHEM., vol. Vol.284, No.7(2009), JPN6018015882, pages 4647 - 4657, ISSN: 0003790498 *
BOTKJAER K. ET AL., BIOCHEM. J., vol. 438(1)(2011), JPN6018015887, pages 39 - 51, ISSN: 0003790499 *

Also Published As

Publication number Publication date
US9908944B2 (en) 2018-03-06
TW201536810A (zh) 2015-10-01
WO2015007727A1 (en) 2015-01-22
US20160159924A1 (en) 2016-06-09
EP3022229A1 (en) 2016-05-25
CN105612183A (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
US9908944B2 (en) Antibodies that bind urokinase plasminogen activator
JP6445596B2 (ja) 抗ｉｌ−２３抗体
JP6696899B2 (ja) プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
AU2009245354B2 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
TWI564305B (zh) 治療性抗體
US11447566B2 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CN101484471B (zh) 抗-nkg2a抗体及其用途
JP7731196B2 (ja) 抗Ｃ１ｓ抗体および使用方法
JP2017503820A (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
JP2011510047A (ja) ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
CN104744591A (zh) β淀粉样蛋白结合蛋白
JP2021521206A (ja) 抗補体成分抗体および使用方法
JP7781820B2 (ja) 抗ヒトｇｐｖｉ抗体を用いた血小板凝集の阻害
US20240166765A1 (en) Inflammatory disease treatment using anti-tissue factor antibodies
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
TW202342517A (zh) 使用抗組織因子抗體之炎性疾病治療
BR122024018245A2 (pt) Anticorpo que se liga ao domínio extracelular do fator tecidual humano (tf), método de produção do mesmo, polinucleotídeo isolado, vetor, célula hospedeira, composição farmacêutica e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180507

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180530